Avadel Pharmaceuticals Plc (AVDL)
21.64
0.00 (0.00%)
USD |
NASDAQ |
Aug 21, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.104B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 46.02% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 90.89% |
Profile
| Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland. |
| URL | http://www.avadel.com |
| Investor Relations URL | https://investors.avadel.com |
| HQ State/Province | Dublin |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 02, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland. |
| URL | http://www.avadel.com |
| Investor Relations URL | https://investors.avadel.com |
| HQ State/Province | Dublin |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 02, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |